Safety and efficacy of topically administered netarsudil (Rhopressa™) in normal and glaucomatous dogs with ADAMTS10‐open‐angle glaucoma (ADAMTS10‐OAG)

Objective To evaluate safety and efficacy of topically administered 0.02% netarsudil ophthalmic solution (Rhopressa™; Aerie Pharmaceutical) in normal and glaucomatous dogs with ADAMTS10‐open‐angle glaucoma (ADAMTS10‐OAG). Animals studied Five normal and 5 glaucomatous Beagle dogs with ADAMTS10‐OAG....

Full description

Saved in:
Bibliographic Details
Published in:Veterinary ophthalmology 2021-03, Vol.24 (S1), p.75-86
Main Authors: Leary, Kelly A., Lin, Kuan‐Ting, Steibel, Juan P., Harman, Christine D., Komáromy, András M.
Format: Article
Language:English
Subjects:
ADAMTS10
Administration, Ophthalmic - veterinary
Animals
Benzoates - administration & dosage
Benzoates - adverse effects
Benzoates - therapeutic use
beta-Alanine - administration & dosage
beta-Alanine - adverse effects
beta-Alanine - analogs & derivatives
beta-Alanine - therapeutic use
dog
Dog Diseases - drug therapy
Dogs
Female
glaucoma
Glaucoma, Open-Angle - drug therapy
Glaucoma, Open-Angle - veterinary
intraocular pressure (IOP)
Intraocular Pressure - drug effects
Male
netarsudil
Pupil - drug effects
Rhopressa
Treatment Outcome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Objective To evaluate safety and efficacy of topically administered 0.02% netarsudil ophthalmic solution (Rhopressa™; Aerie Pharmaceutical) in normal and glaucomatous dogs with ADAMTS10‐open‐angle glaucoma (ADAMTS10‐OAG). Animals studied Five normal and 5 glaucomatous Beagle dogs with ADAMTS10‐OAG. Procedures In each dog, left or right eye was randomly selected for netarsudil treatment. Contralateral eyes were sham‐treated with balanced salt solution (BSS). Following a 1‐week baseline period, dogs were treated once daily (q24h) during week 2, and twice daily (q12h) during week 3; week 4 served as washout period. Efficacy was measured by diurnal intraocular pressure (IOP) and pupil diameter. Safety was assessed by routine ophthalmic examination, gonioscopy, and pachymetry. Differences in least square means of quantitative outcome measures were compared between netarsudil and BSS sham‐treated eyes by linear Gaussian model. Results Baseline IOPs were 18.5 ± 0.5 mm Hg (mean ± SEM) in normal and 27.8 ± 1.0 mm Hg in OAG dogs. Even though mean IOPs were lower in netarsudil‐ vs sham‐treated eyes, the overall differences were neither significant nor clinically relevant, regardless of treatment frequency (q24h‐normal: sham 16.4 ± 1.1 mm Hg vs treatment 15.6 ± 1.0 mm Hg; q24hr‐OAG: sham 25.8 ± 2.3 mm Hg vs. treatment 25.7 ± 2.4 mm Hg; q12hr‐normal: sham 15.4 ± 0.8 mm Hg vs. treatment 14.4 ± 0.8 mm Hg; q12hr‐OAG: sham 26.3 ± 1.7 mm Hg vs. treatment 25.4 ± 1.8 mm Hg). Netarsudil administration was well tolerated but resulted in significant, moderate‐to‐severe conjunctival hyperemia (P 
ISSN:1463-5216
1463-5224
DOI:10.1111/vop.12734